Long-Acting Injectable Medications in Mental Health
Springer International Publishing (Verlag)
978-3-032-09414-8 (ISBN)
Long-Acting Injectable Medications in Mental Health describes the currently available long-acting injectable (LAI) medications to treat mental health and substance use disorders. Each chapter details how the medication's LAI technology utilized by the formulation, the dosing parameters, including missed dosing, pharmacokinetic properties, drug interactions, adverse effects, and preparation and administration instructions. Additionally, each medication chapter describes the efficacy of the formulation in comparison to other LAIs and oral medications. The book provides insight into how to approach a patient to engage in a conversation regarding LAI options. Switching strategies between agents and discontinuation options for patients are also included. Clinical pearls and tips on the role of these medications in clinical practice are provided to assist providers and pharmacists with the selection of agents and best practices regarding their use. A chapter is devoted to the use of LAIs in special populations (pregnant and lactating patients, older adults, pediatrics).
The book is unique in that it encompasses all aspects of LAIs, from conversation to selection to administration and beyond. As this marketplace continues to increase, LAIs are becoming a mainstay of therapy for those with serious mental illness and substance use disorders. This book highlights the differences in products and the importance of understanding these differences to have the best outcome for the patient. Many providers are not familiar or comfortable with these formulations, but this book provides pharmacists and other healthcare providers, who are positioned to discuss these options with patients, with a highly accessible and comprehensive resource.
Megan J. Ehret, PharmD, MS, BCPP
Professor and Co-Director of Mental Health Program
University of Maryland, School of Pharmacy
Introduction.- History of LAIs.- Brief guidance on use of LAIs- where are the current guidelines.- Evidence of Effectiveness.- First Generation Antipsychotic LAIs.- Haloperidol.- Fluphenazine.- Aripiprazole Products.- Abilify Maintena.- Abilify Asimtufii.- Aristada (to include Initio).- Paliperidone.- Invega Sustenna.- Invega Trinza.- Invega Hafyera.- Risperidone.- Risperdal Consta (to include information on generic availability).- Perseris.- Uzedy.- Rykindo.- Olanzapine.- Zyprexa Relprevv.- Naltrexone.- Vivitrol.- Buprenorphine.- Sublocade.- Brixadi.- Special Populations.- Pediatrics.- Older Adults.- Pregnancy and Lactation.- Approaching the Patient and Successful Utilization.- Successful discussions.- Clinic set-up.- Pharmacist Administration.- Future of LAIs.- Discussion of future products and where practice is headed.- Conclusion.- Medication Reference Tables.
| Erscheinungsdatum | 22.11.2025 |
|---|---|
| Zusatzinfo | XXVI, 128 p. 2 illus., 1 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Psychiatrie / Psychotherapie | |
| Medizin / Pharmazie ► Pharmazie ► PTA / PKA | |
| Schlagworte | Antipsychotics • discontinuing long-acting injectables • first generation antipsychotic • LAI administration • LAI dosing • LAI formulation • Lais • long-acting injectables • mental health medication • Mental Health Treatment • psychiatric medications • second generation antipsychotic • substance abuse treatment • switching long-acting injectables |
| ISBN-10 | 3-032-09414-3 / 3032094143 |
| ISBN-13 | 978-3-032-09414-8 / 9783032094148 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
